Abstract
BackgroundRecently, the safety of JAK inhibitors in the treatment of rheumatoid arthritis(RA) about malignancy and major adverse cardiac events has been highlighted [1], but there are still few reports on...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
